We are the world’s largest publicly-funded international collaboration focused on the development of vaccines to prevent HIV/AIDS. Learn more >
Our sites conduct all phases of clinical trials - from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy. Learn more >
Worldwide, thousands of people have participated in HIV vaccine trials. Volunteers are the heroes of vaccine development. Learn more >
On this HIV Vaccine Awareness Day 2016, I’m actually thinking of another date: June 5, 1981. It was 35 years ago that the very first report of what came to be known as AIDS was published in the US Center for Disease Control’s weekly MMWR report. That report said that 5 young men, all “active homosexuals” at 3 different hospitals in Los Angeles, California were being treated for Pneumocystis carinii pneumonia, as well as previous or current cytomegalovirus (CMV) infections; both are rare diseases that could signal… Read more.
The HVTN and HIV Prevention Trials Network (HPTN) will be partnering for the first ever proof of concept trials to test a new idea that offers great promise to prevent new infections.
This new idea is called Antibody Mediated Prevention, or more simply, “AMP.” The goal of AMP is to prevent HIV infection using a broadly neutralizing antibody (BNAb)... Read more.
The Mbeya region in Tanzania is a remote, rural area that encompasses two major highways and is adjacent to two international borders. In the late 1980s, the HIV epidemic rapidly expanded in the Mbeya region, fueled by these unique geographic features and exacerbated by a lack of trained health staff, shortage of medicine, and a poor healthcare infrastructure. Read More.
We support the next generation of HIV researchers with structured mentoring, projects, training, and networking opportunities. Learn more >
Getting the right test will prevent an incorrect diagnosis of HIV. Your study site or VISP Testing Service can provide the right test. Visit our frequently asked questions for more information.